Related Experiment Video
Updated: Apr 9, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease
Yue Yang1, C Dirk Keene, Elaine R Peskind
1From the Department of Pathology, University of Washington, Seattle, WA (YY, CDK, EC, AMW, KSM, JZ, GSB, TJM); Department of Psychiatry & Behavioral Sciences, University of Washington, Seattle, WA; (ERP, GL); VA Northwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, WA (ERP); Department of Neurosciences, University of California San Diego, La Jolla, CA (DRG); Department of Neurology, University of Washington, Seattle, WA (S-CH); Department of Medicine, University of Washington, Seattle, WA (C-EY); Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, WA (C-EY); Department of Laboratory Medicine, University of Washington, Seattle, WA (GSB); and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (BTH).
Abstract:
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) β42-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE ε4/ε4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE ε3/ε3 or APOE ε3/ε4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and β-amyloid (Aβ42)-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cerebrospinal Fluid
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

